| Identification | Back Directory | [Name]
2-Thiazolecarboxamide, 5-[2,3-dichloro-4-[2,2,2-trifluoro-1-hydroxy-1-(trifluoromethyl)ethyl]phenyl]-N-(2-hydroxy-2-methylpropyl)-4-[[(2R)-2-methyl-1-pyrrolidinyl]carbonyl]- | [CAS]
1917306-14-9 | [Synonyms]
tert-butyl (3R
4R)-3-fluoro-4-hydroxypiperidine-1-carboxylate
2-Thiazolecarboxamide, 5-[2,3-dichloro-4-[2,2,2-trifluoro-1-hydroxy-1-(trifluoromethyl)ethyl]phenyl]-N-(2-hydroxy-2-methylpropyl)-4-[[(2R)-2-methyl-1-pyrrolidinyl]carbonyl]- | [Molecular Formula]
C23H23Cl2F6N3O4S | [MOL File]
1917306-14-9.mol | [Molecular Weight]
622.41 |
| Hazard Information | Back Directory | [Description]
JNJ-61803534 is a novel potent RORγt inverse agonist, selectively inhibiting RORγt-driven transcription versus closely-related family members, RORα and RORβ, also inhibiting IL-17A production in human CD4+ T cells under Th17 differentiation conditions, but not inhibiting IFNγ production under Th1 differentiation conditions, and having neither impact on in vitro differentiation of regulatory T cells (Treg), nor on the suppressive activity of natural Tregs. |
|
|